Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation (Heart-BEAT): A Cohort Study Based on CPRD-HES Data
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 18 May 2017
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 09 May 2017 Planned End Date changed from 1 Aug 2018 to 31 Aug 2019.
- 09 May 2017 Planned primary completion date changed from 1 Aug 2017 to 31 Aug 2018.
- 22 Nov 2016 New trial record